Opendata, web and dolomites

MeningoSpeed SIGNED

A unique cost-effective and point of care (PoC) kit for the non-invasive rapid in vitro diagnosis of meningococcal disease

Total Cost €


EC-Contrib. €






 MeningoSpeed project word cloud

Explore the words cloud of the MeningoSpeed project. It provides you a very rough idea of what is the project "MeningoSpeed" about.

biospeedia    accurate    business    gt    cagr    projected    added    3h    deaths    lethality    care    burden    worldwide    france    mainly    company    diagnostic    profit    health    serogroups    commercial    sensitivity    cheaper    opportunity    six    caused    pcr    physicians    epidemic    spin    technological    meningitidis    infectious    monitoring    sequelae    capability    abcxwy    vs    68    faster    limited    meningococcal    point    accuracy    healthcare    successful    nanoparticle    purchasers    disruptive    core    off    societal    treatment    secure    meningospeed    performance    people    direct    source    latex    children    least    diagnosis    nm    costly    45    hospital    demonstrated    reducing    disease    accumulated    invasive    10    annually    savings    tests    93    vast    market    ca    million    finalize    tools    rapid    financial    2026    acute    competitive    diseases    agglutination    despite    neisseria    feasibility    net    md    profitable    first    unmet    lt    gold    min    alternatives    plan    vitro    launch    permanent    patients    young    lack    solution    fashion    33    specificity    25    15    immunochromatographic    valued    2022    public    tool    pasteur   

Project "MeningoSpeed" data sheet

The following table provides information about the project.


Organization address
city: PARIS
postcode: 75724
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2019-06-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOSPEEDIA FR (PARIS) coordinator 50˙000.00


 Project objective

Meningococcal disease (MD), caused by Neisseria meningitidis serogroups (mainly ABCXWY), annually affects 1.2 million people worldwide (mainly children and young). Due to its high lethality (8-15% treated patients), permanent sequelae and epidemic potential, MD represents a major public health problem. Despite the societal burden, there is a lack of rapid and accurate diagnostic tools for timely and early treatment that results very costly for healthcare systems (e.g. direct costs valued in € 68 m/hospital/year). In response to the unmet need, BioSpeedia (spin-off from the Institute Pasteur, France) has vast experience in infectious diseases management and is developing the first-ever gold nanoparticle-based immunochromatographic test with demonstrated diagnostic capability for the six Nm serogroups. MeningoSpeed is a non-invasive, accurate (sensitivity and specificity >93%), rapid (<15 min vs PCR: 3h) and cost-competitive in vitro diagnostic test (€45 sample, at least 25 % cheaper than latex agglutination tests and PCR alternatives) for MD diagnosis. Our one-step solution will result on added value for patients, physicians and healthcare purchasers by improving disease monitoring in an accurate and timely fashion way, reducing deaths and sequelae. MeningoSpeed will provide healthcare systems with limited resources with a reliable and cost-effective diagnostic tool, leading to significant cost-savings. MeningoSpeed´s high accuracy and performance under a faster and cheaper cost make it a disruptive solution with great potential for commercial success in the growing point-of-care market (€33 B by 2022, CAGR 10%). Thus, MeningoSpeed is projected to be a profitable business opportunity and a core source of growth for the company (ca. €33 M of accumulated net profit during 2022-2026). A next feasibility study covering the technological, commercial and financial issues will enable us to finalize our business plan and secure our steps towards the successful market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MENINGOSPEED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MENINGOSPEED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  


Automated, Fast Generation of High-Performance Instruction Set Simulators for Microprocessors

Read More  

RV by RE (2019)

Rabbit-View by Rabbit-Eyes

Read More